Italia markets closed

ANIK May 2024 30.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,05000,0000 (0,00%)
In data: 03:24PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0500
Aperto0,4000
Denaro0,0000
Lettera0,0500
Prezzo d'esercizio30,00
Scadenza2024-05-17
Min-Max giorno0,0500 - 0,4000
Contratto - Min-MaxN/D
Volume2
Open Interest83
  • GlobeNewswire

    Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023

    BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-844-826-303

  • GlobeNewswire

    Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting

    RevoMotion™ Reverse Shoulder System showing smallest diameter threaded glenoid baseplate RevoMotion™ Reverse Shoulder System showing smallest diameter threaded glenoid baseplate Integrity™ Implant System Integrity™ Implant System RevoMotion Reverse Shoulder Arthroplasty System significantly expands Anika’s shoulder arthroplasty portfolio and provides a bone conserving and innovative solution in the $1 billion1 U.S. reverse shoulder market RevoMotion adds to a growing, highly differentiated portf

  • GlobeNewswire

    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 5, 2023, Anika granted restricted stock units ( “RSUs”) covering 10,000 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, was approved by the compensation committee of the board of directors pursuant to a